Welcome to our dedicated page for Biomarin Pharmaceutical news (Ticker: BMRN), a resource for investors and traders seeking the latest updates and insights on Biomarin Pharmaceutical stock.
BioMarin Pharmaceutical Inc. develops and commercializes medicines for rare genetic diseases, with recurring news centered on commercial portfolio performance, regulatory approvals, clinical data and business development. Company updates commonly reference therapies for achondroplasia, phenylketonuria, hemophilia, mucopolysaccharidosis and lysosomal storage diseases, including VOXZOGO, PALYNZIQ, GALAFOLD and POMBILITI + OPFOLDA.
BioMarin news also covers financial results, guidance, acquisition integration, debt financing and governance changes. Clinical and regulatory announcements focus on genetically defined conditions, skeletal disorders, enzyme-based therapies and investigational rare-disease programs such as DMX-200 for focal segmental glomerulosclerosis.
BioMarin Pharmaceutical (BMRN) reported its Q2 2020 financial results, with total revenues rising to $429.5 million, an 11% increase year-over-year. Net product revenues grew by 4% to $386.8 million, driven by significant increases in Palynziq (116%) and Aldurazyme (457%). However, Vimizim and Naglazyme revenues fell by 5% and 18%, respectively. The company reported a GAAP net loss of $29.2 million, an improvement from a loss of $37.4 million last year. With cash reserves reaching $1.7 billion, BioMarin is focused on upcoming product approvals, particularly for its gene therapies. Full-year GAAP net income guidance is now set at $720-$980 million.
BioMarin Pharmaceutical (NASDAQ: BMRN) submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vosoritide, a treatment aimed at children with achondroplasia. This application follows a Phase 3 study confirming its safety and efficacy. If approved, vosoritide will be the first medicine targeting achondroplasia in Europe. The company plans to file a New Drug Application (NDA) with the FDA in Q3 2020. Vosoritide has received Orphan Drug designation from the FDA and EMA, highlighting its significance in addressing a rare condition.
BioMarin Pharmaceutical will host a conference call on August 4 at 4:30 p.m. ET to discuss its second quarter 2020 financial results and provide a business update. The call will feature Jean-Jacques Bienaimé, CEO, and will be available for replay on the company's website for one week after the event. Interested parties can join via the provided U.S. and international dial-in numbers.
BioMarin Pharmaceutical has promoted Brian R. Mueller to Executive Vice President, Chief Financial Officer, and Andrea L. Acosta to Group Vice President, Chief Accounting Officer. Mueller has been with the company for 17 years and served as acting CFO since February 2020. The CEO, Jean-Jacques Bienaimé, expressed confidence in Mueller's leadership and the depth of talent within the finance organization. Mueller aims to support the development of therapies for rare diseases, while Acosta emphasizes the need for a finance team sensitive to innovation requirements.
BioMarin Pharmaceutical announced participation in the BofA Securities 2020 Napa Biopharma Conference on June 24, 2020, at 11:30 AM ET. Key representatives, Henry Fuchs, M.D., President of Worldwide Research & Development, and Brian Mueller, Acting CFO, will present. The event will feature a live audio webcast accessible via the company's investor site. BioMarin focuses on innovative therapies for serious rare disorders, with six commercialized products and numerous candidates in development.
BioMarin Pharmaceutical has released new data from a four-year update of its Phase 1/2 trial for valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, presented by Professor John Pasi. Results indicate a 95% reduction in Annualized Bleed Rate (ABR) to 0.8 from a baseline of 16.3 after four years. Notably, 86% of participants were bleed-free in the fourth year, and there was a 96% reduction in Factor VIII usage. The FDA is reviewing the therapy for approval, with a PDUFA date set for August 21, 2020. The safety profile remains consistent, with no severe adverse events reported.